8-K: Waters Corporation Outlines Growth Strategy at J.P. Morgan Healthcare Conference

Waters Corporation presented its growth strategy and financial performance at the J.P. Morgan Healthcare Conference, highlighting its strong business model and future opportunities.

Summary

• Waters Corporation presented at the J.P. Morgan Healthcare Conference on January 13, 2025, outlining its business performance and growth strategy.
• The company serves regulated markets with a total addressable market of $12 billion, with an additional $7 billion in faster-growing adjacencies.
• Waters has a strong installed base of over 170,000 instruments and a business model focused on liquid chromatography and mass spectrometry.
• The company's trailing twelve-month revenue is $2.9 billion, with an adjusted operating margin of 30.7% and a gross margin of 59.7%.
• Approximately 75% of Waters' revenue is tied to resilient growth drivers, including pharma discovery, development, and manufacturing.
• Waters has implemented a transformation plan since 2020, focusing on commercial innovation and entering faster-growing segments.
• The company has seen a return to growth in instruments after seven consecutive quarters of decline, with total 3Q24 year-over-year sales growth of 5% in constant currency.
• Waters is targeting long-term growth through new replacement cycles, increased recurring revenue, and expansion into new applications and markets.
• The company expects to expand its adjusted operating margin by 100 basis points annually through volume leverage, pricing, and productivity initiatives.
• Waters is also positioned for M&A to unlock additional EPS growth.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Waters, highlighting its strong business model, growth opportunities, and margin expansion potential. While there are some challenges mentioned, the overall tone is optimistic and forward-looking.

Positives

• Waters has a strong business model with a large installed base and recurring revenue streams.
• The company is experiencing a return to growth in instruments after a period of decline.
• Waters has a high adjusted operating margin of 30.7%, indicating strong profitability.
• The company is expanding into faster-growing market segments, such as bioseparations and clinical diagnostics.
• Waters is focused on innovation, with new product launches in chemistry, liquid chromatography, and mass spectrometry.
• The company is well-positioned to benefit from long-term growth drivers, such as the increasing demand for biologics and novel modalities.
• Waters has a strong free cash flow generation, averaging 23% of sales over the past five years.
• The company is actively pursuing margin expansion through volume leverage, pricing, and productivity initiatives.
• Waters is uniquely positioned for M&A to further enhance growth and capabilities.

Negatives

• The company experienced a decline in instrument sales for seven consecutive quarters.
• Waters faced headwinds from a challenging market environment, including volume pressures and inflationary pressures.
• The company's growth in China has been slower than in other regions.
• The company's historical instrument growth has been relatively low compared to its recurring revenue growth.

Risks

• The company's future performance is subject to risks and uncertainties, including those associated with the Wyatt acquisition.
• Economic, environmental, regulatory, sovereign, and political uncertainties could impact Waters' operating results.
• The company's ability to realize the expected benefits of its cost-saving initiatives is not guaranteed.
• The company's growth rates are based on internal estimates and are subject to change.
• The company's expansion into new markets and applications may not be successful.

Future Outlook

Waters anticipates a new replacement cycle for its instruments, increased recurring revenue, and expansion into new applications and markets, leading to long-term growth and margin expansion. The company expects to expand its adjusted operating margin by 100 basis points annually through volume leverage, pricing, and productivity initiatives. They also see M&A as a key driver of future growth.

Management Comments

• Management believes that non-GAAP financial measures are important in comparing current results with prior period results.
• Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety.

Industry Context

Waters' presentation highlights its position in the life science tools industry, particularly in analytical instruments. The company's focus on regulated markets and its expansion into faster-growing segments aligns with industry trends. The company's performance is compared to its peers in the life science tools sector, showing a differentiated margin performance.

Comparison to Industry Standards

• Waters' adjusted operating margin of 30.7% is compared to peers in the life science tools industry, with Waters showing a higher margin than most.
• The company's free cash flow as a percentage of sales is also compared to peers, with Waters showing a strong performance.
• Waters' service satisfaction score is noted as the highest among all instrument vendors, according to SDi 2024 Analytical & Life Science Instrumentation Service Market.
• Waters' tNPS score is over 20 points higher than the benchmark average, according to TSIA, 2024.

Stakeholder Impact

• Shareholders are expected to benefit from the company's growth strategy and margin expansion.
• Employees may benefit from the company's growth and expansion into new markets.
• Customers are expected to benefit from the company's innovative products and services.
• Suppliers may benefit from the company's increased demand for its products and services.

Next Steps

• Waters will host its 2025 Investor Day on March 5, 2025, in New York City.
• The company will continue to execute its growth strategy, focusing on commercial innovation and expansion into new markets.

Key Dates

Keywords

Liquid Chromatography, Mass Spectrometry, Pharmaceutical, Bioseparations, Clinical Diagnostics, Analytical Instruments, Recurring Revenue, Operating Margin, Growth Strategy, M&A